Dr. Kozarich has nearly 40 years of experience in the biopharmaceutical industry and academia. Dr. Kozarich currently serves as Chairman of Ligand Pharmaceuticals, and Chairman and President of ActivX Biosciences. Prior to his role at ActivX, Dr. Kozarich was Vice President at Merck Research Laboratories where he was responsible for a variety of drug discovery and development programs and external biotech collaborations. Dr. Kozarich previously held full professorships at the University of Maryland and Yale School of Medicine. He was named Director of the Year for 2014 by the Corporate Directors Forum, has been an American Cancer Society Faculty Research Awardee, and received the Distinguished Scientist Award of the San Diego Section of the American Chemical Society. Dr. Kozarich holds a B.S. in chemistry from Boston College and a Ph.D. in biological chemistry from the Massachusetts Institute of Technology and was an NIH Postdoctoral Fellow at Harvard University.
Mr. Meckler has held a variety of roles over in both large and small biopharma companies. Most recently, Mr. Meckler was the CEO of Cocrystal Pharma, transforming it into a clinical company. Additionally, he has held led companies like QLT, Inc. and Cypress Bioscience through transformational times. Mr. Meckler is currently a director and former Chairman of Retrophin. Mr. Meckler started his career in life sciences with Pfizer, Inc., eventually becoming a member of the Corporate Finance Leadership Team and overseeing acquisition and divestiture activities. Mr. Meckler holds a B.S. in Industrial Management and a M.S. in Industrial Administration from the Tepper School of Business at Carnegie Mellon University. Additionally, he received his J.D. from Fordham University’s School of Law.
Mr. Weiss has been our Chief Executive Officer since October 2014 and has served on our board of directors since October 2014. Prior to that, he served as our Co-Chief Executive Officer from November 2013 until October 2014. Prior to serving as our Co-Chief Executive Officer, he served as our Executive Vice President of Commercial Operations commencing in September 2006. Mr. Weiss has approximately 15 years of experience in healthcare corporate development, strategic planning and corporate finance. Prior to his service with us, Mr. Weiss served as the Head of Life Sciences Strategic consulting with PricewaterhouseCoopers Israel, an accounting firm, from 2002 until 2006. He is a certified public accountant in Israel, and has a BSc in Biology, a B.A. in accounting and has completed MSc studies in neuro-biochemistry, each from Tel Aviv University in Tel Aviv, Israel.
Mr. Carni has over 35 years of experience in the global pharmaceutical industry throughout Israel and North America. Mr. Carni has held various executive positions in the “Agis Group”, a leading Israeli pharmaceutical group. Mr Carni served as Intec Pharma CEO from 2006 until 2014 and before that he served as President and CEO of Clay Park Labs in New York for more than 10 years. He has a degree in industrial engineering from the Technion in Haifa, Israel.
Mr. Joseph is an international financier and entrepreneur with more than 18 years of experience in the pharmaceutical and medical device industry. He is the founder of two companies, Optical Mammograph and Intec Pharma. Since 2002, Mr. Joseph has served as the active chairman at Intec until March 2016. Mr. Joseph is an expert in business, financial and strategic planning. To date, he has raised more than $90 million for Intec from private investors and institutions. He also led Intec’s successful IPO on the Tel Aviv Stock Exchange (TASE) in February 2010. Mr. Joseph began his career as the head of marketing at ADGAR, a TASE-traded company. He studied at Regent’s College at the European Business School in London and holds a BSC in business administration from Mercy College in New York.
Mr. Gil Bianco has served as one of our external directors since April 2010. From November 2009 to November 2012, Mr. Bianco served as a director of D-Pharm Ltd., an Israeli public biopharmaceutical company, and from May 2007 to May 2010, Mr. Bianco served as a director of BioLineRx Ltd. (NASDAQ: BLRX), a clinical-stage biopharmaceutical development company. From December 2003 to December 2009, Mr. Bianco served as an external director of the Tel Aviv Stock Exchange Ltd. Prior to that, from 2001 to 2003, Mr. Bianco served as chief executive officer of Agis Industries Ltd., a pharmaceutical manufacturer. Mr. Bianco currently serves as an external director at Mazor Robotics Ltd. (NASDAQ: MZOR and TASE: MZOR.TA), a medical device company. Mr. Bianco is also a director of several private companies in the fields of biotech and medical devices. Mr. Bianco holds a B.A. in economics and accounting from Tel-Aviv University in Tel-Aviv, Israel and is a certified public accountant in Israel.
Ms. Hila Karah has served as one of Intec Pharma’s directors since December 2009. Ms. Karah was the chief investment officer of Eurotrust Ltd., an investment company, from 2006 until 2013, where she focused primarily on making early-stage investments in life science companies. Ms. Karah has been a private and public equity investor in several high-tech, bio-tech and internet companies since 1999. Prior to joining Eurotrust, she served as a partner and financial analyst at Perceptive Life Sciences Ltd., a New York-based hedge fund. Prior to her position at Perceptive Life Sciences, Ms. Karah was a research analyst at Oracle Partners Ltd., a healthcare-focused hedge fund based in Connecticut. Ms. Karah currently serves as a director at Cyren Ltd., a publicly-traded technology and security company (NASDAQ CYRN), a director of Labstyle Innovations Ltd., a publicly-traded biodiagnostics company headquartered in Israel (OTCMKTS: DRIO) and from May 2011 until May 2013, Mrs. Karah served as a director of Glycominds Ltd., a publicly-traded Israeli biodiagnostics company (TASE: GLCM). She has a B.A. in molecular and cell biology from the University of California, Berkeley, in Berkeley, California and has studied at the University of California, Berkeley – University of California, San Francisco School of Medicine Joint Medical Program.
Mr. Issac Silberman has served as one of our external directors since April 2010. Since 2007, Mr. Silberman has also served as a special investment advisor at Sullam Holdings L.R. Ltd., a financial services corporation in the Lenny Recanati Group, focusing primarily on investments in high-tech, biotechnology and real estate companies. Mr. Silberman also serves as a director in other private Israeli companies, and has over 20 years of prior experience as an executive officer of various public and private companies. Mr. Silberman holds a B.A. in economics and accounting from Tel Aviv University in Tel Aviv, Israel, and he is a certified public accountant in Israel.